Denali Capital Acquisition Corp. (DECA) to Combine with Semnur Pharmaceuticals in $2.5Bn Deal

Denali Capital (NASDAQ:DECA) has entered into a definitive agreement to combine with Semnur Pharmaceuticals at an equity value of $2.5 billion. Palo Alto, California-based Semnur is developing a non-opioid injectable pain treatment for lower back disorders. The combined company is expected to trade on the Nasdaq under the symbol “SMNR” once the deal is completed
Read More